NEXTSTELLIS
Peakdrospirenone and estetrol
NDAORALTABLET
Approved
Apr 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
NEXTSTELLIS (drospirenone and estetrol) is ovulation. First approved in 2021.
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEXTSTELLIS is an oral contraceptive tablet combining drospirenone and estetrol, a novel fourth-generation progestin paired with a natural estrogen. It prevents ovulation and is indicated for contraception in women of reproductive age. The unique estetrol component represents a differentiated estrogen option in the crowded oral contraceptive market.
$0.078MPart D
Peak17.4 years to LOEEarly peak-stage product with minimal Part D penetration suggests significant untapped market opportunity and sustained commercial team investment through the decade.
Mechanism of Action
ovulation.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NEXTSTELLIS offers a career opportunity in a peak-stage, well-protected small-molecule product with significant runway until LOE in 2043. The competitive lack of direct rivals and minimal Part D claims suggest substantial upside potential for commercialization professionals building market share in the contraceptive category.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.